Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11113
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcMahon, L Pen
dc.contributor.authorDawborn, J Ken
dc.date.accessioned2015-05-16T00:42:02Z
dc.date.available2015-05-16T00:42:02Z
dc.date.issued1990-05-16en
dc.identifier.citationAmerican Journal of Nephrology; 10(5): 404-8en
dc.identifier.govdoc2080791en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11113en
dc.description.abstractTwelve stable haemodialysis patients were divided into two groups and given recombinant human erythropoietin (r-HuEPO) for 14 weeks either intravenously (i.v.) or subcutaneously (s.c.). Dosage was 25 units/kg either thrice (i.v.) or twice (s.c.) per week for 7 weeks, and then 50 units/kg for a further 7 weeks. Response to s.c. therapy was comparable to i.v. despite a 33% lower weekly dosage, and was significant at both 7 (i.v.: 1.1 +/- 0.3, mean +/- SEM, p = 0.02; s.c.: 0.8 +/- 0.3 g/dl, p = 0.03) and 14 weeks (i.v.: 2.8 +/- 0.5, p = 0.003; s.c.: 2.6 +/- 0.6 g/dl, p = 0.009). A correlation was observed between response to r-HuEPO and initial ferritin levels (r = 0.63, p = 0.04). One patient required an increase in antihypertensive medication and there was one arteriovenous fistula thrombosis. Results suggest that overall s.c. therapy is as effective as i.v. therapy, and that a good response with few side effects can be obtained using relatively low doses of r-HuEPO.en
dc.language.isoenen
dc.subject.otherAnemia.drug therapy.etiologyen
dc.subject.otherDrug Administration Scheduleen
dc.subject.otherErythropoietin.administration & dosage.therapeutic useen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherInjections, Intravenousen
dc.subject.otherInjections, Subcutaneousen
dc.subject.otherKidney Failure, Chronic.complications.therapyen
dc.subject.otherMaleen
dc.subject.otherRecombinant Proteins.administration & dosage.therapeutic useen
dc.subject.otherRenal Dialysisen
dc.titleExperience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin.en
dc.typeJournal Articleen
dc.identifier.journaltitleAmerican journal of nephrologyen
dc.identifier.affiliationDepartment of Medicine, Austin Hospital, Heidelberg, Victoria.en
dc.description.pages404-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2080791en
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.